The Obesity ETF (SLIM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
Foundayo (orforglipron) has a serious advantage over Novo Nordisk's Wegovy pill. Retatrutide, a subcutaneous triple hormone receptor agonist in phase 3 trials, could be a game changer.
Wave Life Sciences Slips as Obesity Data Fails to Convince
Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets following updated Phase 1 INLIGHT trial data for WVE-007, the company's obesity candidate.
Novo Nordisk Says Experimental Diabetes and Obesity Drug Shows Positive Results
The drugmaker said UBT251 achieved mean body weight reduction of up to 9.8% after a 24-week trial.
Why Eli Lilly Remains My Top Obesity Bet
Despite HSBC downgrading Eli Lilly and Company stock, it remains my favorite in the obesity treatment market. That's also because LLY's tirzepatide franchise sales grew 114.6% year-on-year to about $11.7 billion in Q4. Meanwhile, on March 19, Eli Lilly published promising clinical data on retatrutide for the treatment of type 2 diabetes.
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on Shares
Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12.
Eli Lilly Stock Downgraded on Inflated Obesity Drug Market
Eli Lilly And Co ( NYSE:LLY) stock is down 2.2% to trade at $967.06 at last glance, after a downgrade at HSBC "reduce" from "hold.
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
Eli Lilly and Co (NYSE: LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound
Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform. The post Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound appeared first on Investor's Business Daily.
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday.
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study
Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study. The post Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study appeared first on Investor's Business Daily.
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's CagriSema Phase 3 results. The company's GIP/GLP-1 agonist, VK2735, appears undifferentiated, facing intense competition from existing and emerging obesity treatments. Plans to launch VK2735 with an auto-injector could delay regulatory approval, offering minimal patient benefit over existing prefilled pens.
